Swine fever. Immunisation of piglets

Vaccination against Swine Fever using the CL Chinese strain can be done in 7-day-old piglets if they are born of non-immune sows. The simultaneous weaning and vaccination emphasises the safety of this strain. The excellent immunity observed confirms the immunocompetence of 7-day-old piglets. In piglets born of immune sows and also weaned at 7 days, passive protection can extend beyond the age of 2 months if the sow is vaccinated several months prior to gestation. The immune level of the piglets would seem to depend on the interval between vaccination of the sow and farrowing and can be attributed to the quality of the antibodies transmitted by the colostrum. Piglets born of sows vaccinated 10 months prior to farrowing can be vaccinated as early as 5 weeks; the protection percentage observed at the age of about 6 months is over 80%. A booster injection at this age then confers immunity to future breeders throughout their economic life, i.e. 4 years in the reported experiment.     

Intestinal defence of the neonatal pig: interrelationship of gut and mammary function providing surface immunity against colibacillosis.

The neonatal requirements for maternal passive immunity and the lactation immunobiology with regard to sow immunisation for neonatal protection are reviewed. A vaccination protocol which combines oral and parenteral antigen administration to produce antibody activity mediated mainly by IgM is described. Its efficacy in affording protection to neonatal piglets was tested against a lethal oral infection with a virulent strain of Escherichia coli "Abbottstown". Piglets suckled on vaccinated or non-vaccinated sows were exposed to an infective challenge in the gastrointestinal tract and the relative pathology in test and control groups observed over the neonatal period. Death ensued in 76 per cent of piglets suckled on control sows and 26 per cent of piglets suckled on sows vaccinated by two intramuscular injections. Litters suckled on orally vaccinated sows were able to resist a similar infective challenge, there being only one fatality out of 42 piglets.     

Effect of L-carnitine supplementation on performance parameters in gilts and sows

The effect of L-carnitine supplementation during pregnancy and lactation on performance parameters of sows was studied. The trial comprised a total of 127 sows (40 gilts, 87 mature sows) which were divided into a control and a treatment group. All animals were fed individually and received basic feed mixtures for pregnancy and lactation with low carnitine concentrations (gestation diet: 4.7 mg/kg feed, lactation diet: 12.5 mg/kg feed). The rations of the sows in the treated group were supplemented with 125 mg L -carnitine per head and day during pregnancy and 250 mg L -carnitine per head and day during lactation. The animals of the control group received identical feed mixtures in identical amounts, but without the L -carnitine supplement. L -carnitine supplementation resulted in higher sow liveweight gains between day 1 and day 85 of pregnancy. The number of piglets per litter and the number born alive did not differ between the control sows and those treated with L -carnitine. However, the L -carnitine-supplemented sows produced only half as many non-viable piglets as the control animals. Moreover, litter weight and mean birth weight of piglets from L -carnitine-treated sows were higher than in the control sows. This effect was more marked in gilts (+8% higher litter weight, +9% higher piglet weight) than in sows (+7% and +6%, respectively). Piglets from sows whose ration was supplemented with L -carnitine showed higher liveweight gains during the suckling period (+12% for gilts, +4% for sows), which is why litter weights post weaning were also higher among the sows treated with L -carnitine than in the control sows (+14% for gilts, +10% for sows). Overall, the study shows that dietary supplementation with L -carnitine during pregnancy and lactation improves the reproductive performance of sows.     

Vaccination of pregnant sows against transmissible gastroenteritis with two attenuated virus strains and different inoculation routes

Summary Two attenuated transmissible gastro-enteritis (T. G. E.) virus strains were used for vaccination experiments in sows. Four different experiments were carried out (see Table 1). In each experiment, 9 sows were vaccinated during pregnancy and 3 sows served as controls. They were kept together in one farrowing house. The sows were due to farrow at about the same time. The sows and their litters were challenged shortly after farrowing by exposing 3 piglets of 2 control litters to virulent TGE virus. The following vaccination schedules were used (see Table 1): twice intramuscularly with TGE-vac (a commercially available TGE-vaccine), one oral administration followed by an intramuscular vaccination with an attenuated TGE Purdue (Pu) strain, twice orally with Pu strain in enteric coated capsules, and one direct intra intestinal administration followed by 2 intramuscular vaccinations or 3 intramuscular vaccinations with the Pu strain. All sows, except most of those treated with enteric coated capsules, seroconverted demonstrably (Table 2). The geometric mean seroneutralization (SN) titer log 2 varied from 4.1 to 7.5 after the first vaccination and from 7.6 to 10 after the second vaccination. None of the vaccination schedules resulted in an effective lactogenic immunity. The morbidity in the piglets was 100% within 3 to 5 days after challenge. The mortality rate varied from 44 to 80% in litters from vaccinated sows and from 71 to 100% in litters from control sows (see Table 3). Clinical signs were observed in 33,3% of the control sows and in 36% of the vaccinated sows. No correlation was found between the titer of SN antibodies in the sera of the piglets and their survival rate (Table 4). A rapid decrease in antibody concentration was observed, during the first week of lactation in milk samples collected from 4 orally and intramuscularly vaccinated sows (Table 5).     

Vaccination of pregnant sows against transmissible gastroenteritis with two attenuated virus strains and different inoculation routes

Summary

Two attenuated transmissible gastro‐enteritis (T. G. E.) virus strains were used for vaccination experiments in sows.

Four different experiments were carried out (see Table 1). In each experiment, 9 sows were vaccinated during pregnancy and 3 sows served as controls. They were kept together in one farrowing house. The sows were due to farrow at about the same time. The sows and their litters were challenged shortly after farrowing by exposing 3 piglets of 2 control litters to virulent TGE virus.

The following vaccination schedules were used (see Table 1): twice intramuscularly with TGE‐vac (a commercially available TGE‐vaccine), one oral administration followed by an intramuscular vaccination with an attenuated TGE Purdue (Pu) strain, twice orally with Pu strain in enteric coated capsules, and one direct intra intestinal administration followed by 2 intramuscular vaccinations or 3 intramuscular vaccinations with the Pu strain.

All sows, except most of those treated with enteric coated capsules, seroconverted demonstrably (Table 2). The geometric mean seroneutralization (SN) titer log 2 varied from 4.1 to 7.5 after the first vaccination and from 7.6 to 10 after the second vaccination.

None of the vaccination schedules resulted in an effective lactogenic immunity. The morbidity in the piglets was 100% within 3 to 5 days after challenge. The mortality rate varied from 44 to 80% in litters from vaccinated sows and from 71 to 100% in litters from control sows (see Table 3). Clinical signs were observed in 33,3% of the control sows and in 36% of the vaccinated sows.

No correlation was found between the titer of SN antibodies in the sera of the piglets and their survival rate (Table 4).

A rapid decrease in antibody concentration was observed, during the first week of lactation in milk samples collected from 4 orally and intramuscularly vaccinated sows (Table 5).     

Vaccines against Aujeszky's disease: evaluation of their efficacy under standardized laboratory conditions

A standardized test was developed to compare the efficacy of Aujeszky's disease virus (ADV) vaccines under laboratory conditions. Per test 3 groups of 6 to 8 sero-negative pigs were used. The first vaccination was done at 10 weeks of age. One group was vaccinated once, another was vaccinated twice and the 3rd served as control. Pigs were challenge exposed to the virulent NIA-3 strain of ADV 12 weeks after the first vaccination. Apart from mortality, average periods of growth arrest, fever and virus shedding after challenge were used as parameters to evaluate vaccine efficacy. Two inactivated and 4 attenuated vaccines were tested. Two attenuated vaccine viruses were excreted after vaccination. Despite maximal standardization, a considerable variation still existed between the experiments in mortality and growth arrest periods of control pigs after challenge. However, the controls were always more severely affected than the vaccinated pigs. All vaccines except one were effective in preventing death after challenge, but none conferred complete protection. Most vaccinated pigs still lost weight, developed fever and shed virus after challenge. Revaccination after 3 or 4 weeks had little effect, particularly with the attenuated vaccines. The results of the present study indicate that 2 of the attenuated vaccines conferred the best protection, 1 attenuated vaccine appeared to be as effective as the 2 inactivated ones, and the 4th attenuated vaccine was least effective.     

Humoral immunity of neonatal swine after FMD vaccination

The possible effect on pig protection after vaccination pregnant sows and their piglets against FMD at various age was examined using the SN test. Three experiments were conducted with three sow in each (8-9 piglets each). In the first experiment sows were not vaccinated but their piglets were vaccinated on 10th, 20th and 60th day of age. In second experiment sows were vaccinated at the end of rest period and in the middle of pregnancy. Pigs from one sow were vaccinated on 10th, from second sow on 20th and from the third sow on the 60th day of age. Pigs which were vaccinated on the 10th and 20th day of age were revaccinated on the 60th day of age. In third experiment sows were vaccinated at the end of the rest period and in the middle of pregnancy. Their piglets were not vaccinated. The conclusion may be drawn that if the epidemiological situation requires, systemic vaccination of all pigs then, on large farms (where pig production is planned) all sows should be vaccinated at the end of the rest period (first vaccination) and on the 55th-60th day of pregnancy. The next vaccination should be done in the middle of the next pregnancy. A vaccination program of piglets, according to our results, should depend on the vaccination program used for their dams.     

Lactogenic immunity to transmissible gastroenteritis (TGE) of swine induced by the attenuated Nouzilly strain of TGE virus: passive protection of piglets and detection of serum and milk antibody classes by ELISA

Piglets of eight sows vaccinated by different routes with the attenuated TGE mutant coronavirus, Nouzilly (N) strain, and piglets from two field seropositive sows were challenged with a virulent TGE strain. On the day of challenge and 10 days after challenge, milk and serum samples from sows were analysed for their level of neutralizing antibodies, total immunoglobulin classes and TGE antibody classes by an ELISA. No direct relationship was seen between the level of protection of the litters and the titres of the different antibody classes on the day of challenge. However, an inverse correlation was seen 10 days after challenge between protection and the level of TGE antibodies.     

Vaccines against Aujeszky's disease: Evaluation of their efficacy under standardized laboratory conditions

Summary

A standardized test was developed to compare the efficacy of Aujeszky's disease virus (ADV) vaccines under laboratory conditions. Per test 3 groups of 6 to 8 sero‐negative pigs were used. The first vaccination was done at 10 weeks of age. One group was vaccinated once, another was vaccinated twice and the 3rd served as control. Pigs were challenge exposed to the virulent NIA‐3 strain of ADV 12 weeks after the first vaccination. Apart from mortality, average periods of growth arrest, fever and virus shedding after challenge were used as parameters to evaluate vaccine efficacy.

Two inactivated and 4 attenuated vaccines were tested. Two attenuated vaccine viruses were excreted after vaccination. Despite maximal standardization, a considerable variation still existed between the experiments in mortality and growth arrest periods of control pigs after challenge. However, the controls were always more severely affected than the vaccinated pigs. All vaccines except one were effective in preventing death after challenge, but none conferred complete protection. Most vaccinated pigs still lost weight, developed fever and shed virus after challenge. Revaccination after 3 or 4 weeks had little effect, particularly with the attenuated vaccines. The results of the present study indicate that 2 of the attenuated vaccines conferred the best protection, I attenuated vaccine appeared to be as effective as the 2 inactivated ones, and the 4th attenuated vaccine was least effective.     

Efficacy of a novel virulence gene-deleted Salmonella Typhimurium vaccine for protection against Salmonella infections in growing piglets

We have previously developed a novel attenuated Salmonella Typhimurium (S. Typhimurium) ΔcpxR Δlon vaccine. This study was carried out to examine whether this vaccine could effectively protect growing piglets against Salmonella infection. Attenuated S. Typhimurium secreting the B subunit of Escherichia coli heat-labile enterotoxin was also used as a mucosal adjuvant. Pregnant sows in groups A and B were primed and boosted with the vaccine and mucosal adjuvant, whereas sows in groups C, D and E received PBS. Piglets in groups A and C were intramuscularly primed with formalin-inactivated vaccine and orally boosted with live vaccine, while piglets in groups B, D and E received PBS. Piglets in groups A, B, C, and D were challenged with a wild type virulent S. Typhimurium at the 11th weeks of age. Colostrum sIgA and IgG titers in vaccinated groups A and B sows were approximately 50 and 40 times higher than those of non-vaccinated groups C, D and E sows (P < 0.001). Serum IgG titers of group A piglets were also significantly higher than those of groups D and E piglets during the study (P < 0.001). Furthermore, no clinical signs were observed in group A piglets during the entire experimental period after the challenge, while diarrhea was observed in many of the piglets in groups B, C, and D. No Salmonella was isolated from fecal samples of the groups A and C piglets on day 14 after challenge, whereas the challenge strain was isolated from several piglets in groups B and D. These results indicate that vaccination of the piglets with the vaccine and mucosal adjuvant in addition to vaccination of their sows induced effective protection against Salmonella infections in the growing piglets.     

Potency of an experimental DNA vaccine against Aujeszky's disease in pigs

Intradermal vaccination with plasmid DNA encoding envelope glycoprotein C (gC) of pseudorabies virus (PrV) conferred protection of pigs against Aujeszky's disease when challenged with strain 75V19, but proved to be inadequate for protection against the highly virulent strain NIA-3. To improve the performance of the DNA vaccine, animals were vaccinated intradermally with a combination of plasmids expressing PrV glycoproteins gB, gC, gD, or gE under control of the major immediate-early promotor/enhancer of human cytomegalovirus. 12.5 microg per plasmid were used per immunization of 5-week old piglets which were injected three times at biweekly intervals. Five out of six animals survived a lethal challenge with strain NIA-3 without exhibiting central nervous signs, whereas all the control animals succumbed to the disease. This result shows the increased protection afforded by administration of the plasmid mixture over vaccination with a gC expressing plasmid alone. A comparative trial was performed using commercially available inactivated and modified-live vaccines and a mixture of plasmids expressing gB, gC, and gD. gE was omitted to conform with current eradication strategies based on gE-deleted vaccines. All six animals vaccinated with the live vaccine survived the lethal NIA-3 challenge without showing severe clinical signs. In contrast, five of six animals immunized with the inactivated vaccine died, as did two non-vaccinated controls. In this test, three of six animals vaccinated with the DNA vaccine survived without severe clinical signs, whereas three succumbed to the disease. Comparing weight reduction and virus excretion, the DNA vaccine also ranged between the inactivated and modified-live vaccines. Thus, administration of DNA constructs expressing different PrV glycoproteins was superior to an adjuvanted inactivated vaccine but less effective than an attenuated live vaccine in protection of pigs against PrV infection. Our data suggest a potential use of DNA vaccination in circumstances which do not allow administration of live attenuated vaccines.     

Field experiments to evaluate the feasibility of eradication of Aujeszky's disease virus by different vaccination schedules.

In the present report, the extent of the reduction in Aujeszky's disease virus (ADV) dissemination achieved when pigs were intensively vaccinated with gI-deleted vaccines under field circumstances, was examined. On widely dispersed breeding-fattening farms, a gI-negative status was most rapidly obtained and the rate of new waves of infections was lowest when the attenuated Bartha strain was administered to both the sows and the fatteners. It was more difficult not only to reach but also to keep a gI-negative status on farms on which the sows were vaccinated with an inactivated vaccine and the fatteners with the attenuated Bartha strain or when the fattening pigs were not vaccinated at all. In a densely populated area, 9 of the 17 farms had gI-positive fatteners at the start of the intensive vaccination programme in which the attenuated Bartha strain was given to both the sows and the fatteners. Antibodies were not detected in the sera of the fatteners of each farm at some time during the experiments, but the fatteners on 7 of the 18 farms still showed antibodies against gI after 20 months of vaccination. At the end of the experiment, the percentage of fatteners with antibodies on these farms was markedly reduced compared with the percentage at the start of the experiment. Therefore, elimination of field virus may be feasible if intensive vaccination is carried out over a sufficiently long period of time. However, the high rate of reinfections experienced either due to reintroduction of the virus or to recrudescence should be a warning against too much optimism, particularly in regions with a dense swine population.     

Simultaneous vaccination of piglets against foot-and-mouth disease and classical swine fever

Six-week-old piglets, born of unvaccinated sows, were vaccinated against foot-and-mouth disease (FMD) with a trivalent, inactivated vaccine containing an adjuvant or vaccinated against classical swine fever (CSF) with a live attenuated vaccine or against both diseases simultaneously at two different sites. The antibody response to the FMD vaccine was not significantly influenced by the simultaneous vaccination against CSF. FMD vaccine administered simultaneously with the CSF vaccine produced a significantly higher antibody response to CSF than occurred with CSF vaccination only.     

Effects of alpha-tocopherol and selenium on pregnant sows and their piglets' immunity and performance

Four groups of 12 pregnant sows of the same genetic background, with similar litter size, living under the same housing conditions and having the same hygienic and nutritional standards, were used. In control animals (gC), a basic feed was provided, in which the dietary level of alpha-tocopherol was 20 mg/kg of feed and that of selenium (Se) was 0.45 mg/kg of feed (standard ration). Sows in the second group (gE) received basic feed supplemented with 30 mg alpha-tocopherol per kg (50 mg/kg of feed, in total). To those in the third group (gSe) basic feed was provided but additionally they were injected with 30 mg Se (sodium selenite) on days 30, 60 and 90 of pregnancy. For the sows in the fourth group (gESe), basic feed was supplemented with 30 mg alpha-tocopherol per kg. In addition they received 30 mg injectable Se (sodium selenite) on days 30, 60 and 90 of pregnancy. The experiment started on day 30 of pregnancy and lasted until weaning day (28 days post-farrowing). It was found that alpha-tocopherol and selenium act synergistically. Piglets born from sows in gESe had the highest immunoglobulin concentration level up to weaning day. All productive and clinical parameters (number of piglets born/litter, number of weaned piglets/litter, and piglets' average body weight at birth and on weaning day) were greater in these piglets in comparison with the animals of the other groups. Diarrhoea problems were minimal in the piglets in gESe.     

Reproductive performance of sows supplemented with dietary L-carnitine over three reproductive cycles.

The effect of L-carnitine supplementation during pregnancy and lactation on the reproductive performance of sows was studied in two separate trials over three reproductive cycles. Both trials were identical in design and conduct but were performed with different animals. The trials comprised of a total of 127 sows (trial 1) and 100 sows (trial 2) which were divided into control and treatment groups. All animals were fed individually and received basic feed mixtures with low native carnitine concentrations. The rations of the sows in the treated group were supplemented with 125 mg L-carnitine per head and day during pregnancy and 250 mg L-carnitine per head and day during lactation. The animals of the control group received identical feed mixtures in identical amounts, but without the L-carnitine supplement. In the first trial, 212 litters were produced and evaluated for number and body weight of the animals, in the second trial, 173 litters were produced. L-carnitine supplementation significantly increased body weight gains of the sows between day 1 and day 85 of weaning. The number of born piglets, stillborn piglets and piglets fit for rearing was not influenced by dietary L-carnitine supplementation. However, L-carnitine supplementation significantly increased the weights of piglets and litters at birth, weight gains of litters during suckling and weights of litters at weaning. These effects of L-carnitine were seen in both trials; they were independent of the age of the sows and remained over three reproductive cycles in which the sows where continuously treated with L-carnitine. Overall, the study shows that dietary supplementation with L-carnitine during pregnancy and lactation improves the reproductive performance of sows over several reproductive cycles, independent of the age of the sows.     

Induction of lactogenic immunity to transmissible gastroenteritis virus of swine using an attenuated coronavirus mutant able to survive in the physicochemical environment of the digestive tract.

A transmissible gastroenteritis (TGE) coronavirus mutant (188-SG), selected as attenuated and resistant to acidity and proteases of the digestive tract of adult pigs, was used as vaccine ("Nouzilly strain") in sows to protect suckling piglets against a challenge exposure carried out with a highly virulent TGEV strain. The pregnant sows were immunized once (42-49 days before farrowing) or twice (42-49 and 7-15 days before farrowing) by the oral, intramuscular or conjunctival route with the 188-SG strain. Sows exposed to virulent TGEV in the field and experimentally infected sows (two oral inoculations during pregnancy) were used as positive controls leading to high protection. The neutralizing antibody response to vaccination and/or infection was studied in serum and milk. No protection against mortality was observed in the litters of (1) the nine seronegative, susceptible sows, with piglet mortality of 65/70, (2) the seven once orally vaccinated sows, with mortality of 44/54, (3) the seven sows vaccinated twice by the conjunctival route, with mortality of 55/76. Moderate protection was observed in (1) the eight sows vaccinated intramuscularly twice with piglet mortality of 36/90, (2) the seven orally and intramuscularly vaccinated sows with piglet mortality of 31/51. In of 3 contrast, improved protection was observed in (1) the 10 sows vaccinated twice orally, with piglet mortality of 23/95, (2) the four naturally infected sows with piglet mortality of 6/41, (3) the six sows experimentally infected with virulent TGEV with piglet mortality of 1/59. No correlation was found between neutralizing antibodies titers in serum and milk and protection rate of the piglets. The results indicate that relative protective lactogenic immunity against TGEV is induced only by repeated ingestion of the attenuated 188-SG strain of TGEV.     

Immunization of sows in an integrated pig-breeding herd using a homologous inactivated Salmonella vaccine decreases the prevalence of Salmonella typhimurium infection in the offspring

The efficacy of a homologous vaccination in preventing infection of suckling piglets with Salmonella (S.) Typhimurium was evaluated after an immunization of pregnant sows using an inactivated herd-specific S. Typhimurium vaccine. Twenty-five pregnant sows were vaccinated three times antepartum. The efficiency of this vaccine regime was assessed by comparison with a control group of 37 sows and their suckling piglets, which were daily treated with enrofloxacin from day 14 antepartum until the day of weaning. From the first day of life until day 142 post-partum, faecal samples of the piglets were collected and analysed for Salmonella shedding. In parallel, systemic antibody responses were monitored using a whole cell-based isotype-specific enzyme-linked immunosorbent assay (ELISA). The bacteriological investigation showed marked effects of vaccination. Salmonella Typhimurium could not be detected in any of the faecal samples of the piglets from the vaccinated sows. In contrast, the piglets of the group with long-time antibiotic treatment shed salmonellae rating to 47.4% of the animals. Furthermore, the offspring from vaccinated sows showed significantly decreased antibody activities of immunoglobulin (Ig)A and IgG. These bacteriological and serological results indicate a significantly lower Salmonella prevalence in piglets of the vaccinated group. As this study shows, the presented strategy of vaccination of pregnant sows with an inactivated Salmonella vaccine seems to be a suitable measure in decreasing Salmonella prevalence in offspring of infected sows.     

Field evaluation of a bioregulator containing live Bacillus cereus spores on health status and performance of sows and their litters

The efficacy of Paciflor, a bioregulator containing live Bacillus cereus CIP 5832 spores, was assessed in sows during late pregnancy and lactation, as well as in their piglets up to the growing phase. Two groups each of 30 pregnant gilts and sows received normal feed (T1 group), or feed with 85 g Paciflor per ton feed (T2 group), from 15 days prior to farrowing up to the end of the lactation period. Furthermore, 15 litters of the T1 group and 15 litters of the T2 group, were offered normal feed from the 5th to the 70th days of life (T1.1 and T2.1 groups, respectively), while the remaining 15 litters each of the T1 and T2 groups received the same feed but including Paciflor at a dose of 100 g/ton (from day 5 to day 49) and 50 g/ton (from day 50 to day 70). These pig litters were T1.2 and T2.2, respectively. No differences were seen between the T1 and T2 groups with respect to the clinical observations (loss of appetite, fever, mastitis, metritis and returns to oestrus, treatments applied, deaths, or removals to the slaughterhouse), gestation length, bodyweight of sows at farrowing or litter-size at birth. However, during lactation, the fat content of the dam's milk was increased (0.46% more fat), the body weight loss of sows was reduced and the number of weaned pigs per sow was increased (0.6 more pigs per litter) after administration of Paciflor (P < 0.05). Weaning to service interval was also reduced by 1 day (P < 0.05). Moreover, piglets receiving Paciflor with their feed (T1.2 and T2.2 groups) showed less incidence of scours and lower mortality compared to the untreated piglets (T1.1 and T2.1 groups), particularly those pigs originating from Paciflor-treated dams (T2.2 group) (P < 0.05). Despite the fact that no difference was seen between groups with regard to the amount of feed consumed, the feed conversion ratio of Paciflor-treated piglets (T2.2 and T1.2) was significantly improved compared to that of the untreated piglets (T2.1 and T1.1) (P < 0.05). With respect to weight gain, for the Paciflor-treated piglets, those born to Paciflor-treated mothers (T2.2) were 0.56 kg heavier than those born to untreated dams (T1.2) (P < 0.05). It is concluded that administration of Paciflor in dams during the end of pregnancy and during lactation, as well as to their offspring during suckling and the flat-deck period is beneficial for the survival and growth of the piglets.     

Stimulation of serum antibody formation in pigs by oral, subcutaneous or combined administration of live porcine rotaviruses or intramuscular inoculation of inactivated porcine rotaviruses in an oil adjuvant]

Only live vaccines prepared from attenuated strains have been used for the specific prophylaxis of rotavirus infections in pigs. These vaccines are administered to sows per os or parenterally to increase the content of antibodies in the blood serum, colostrum and milk, and in this way to provide for the better passive protection of suckling piglets through the maternal antibodies, or to induce the active immunity by pig vaccination. The data on the efficiency of live vaccines administered in both ways differ as to their ability to stimulate significantly increases in the actual levels of antibodies in sows and also as to the possibility of inducing the protection of vaccinated pigs from virulent virus infection. The objective of our trials was to compare the intensity of antibody response evoked by pig vaccination with live virus if the virus was implanted in different ways, and by vaccination with inactivated virus emulsified in oil adjuvant. The live vaccine consisted of a suspension of porcine rotavirus, strain OSU/6, cultivated in MA-104 culture medium with the content of 10(7) TKID50.ml-1, the inactivated vaccine was the identical virus suspension inactivated by an addition of 0.2% formaldehyde during 24 hours at a temperature of 37 degrees C, emulsified in oil adjuvant by means of an ULTRATURAX equipment at a 4:1 ratio.(ABSTRACT TRUNCATED AT 250 WORDS)     

Immunogenicity in Aujeszky's disease virus structural glycoprotein gVI (gp50) in swine.

Aujeszky's disease virus (ADV) envelope glycoprotein gVI (gp50) was purified from virus-infected Vero cells by ion-exchange and immunoaffinity chromatography and its usefulness as a subunit vaccine was evaluated in active and passive immunization studies. Four-week-old piglets were immunized intramuscularly (IM) with purified gVI twice two weeks apart and challenged intranasally (IN) 10 days after the second immunization with 30 LD50 (10(8)PFU) of a virulent strain of ADV. Pigs, vaccinated with 100 micrograms of purified gVI, produced virus neutralizing antibodies and did not develop clinical signs after challenge exposure. The challenge virus was not isolated from nasal swabs and tonsils of gVI-vaccinated pigs, whereas non-vaccinated control pigs developed illness after challenge exposure with the same virulent ADV strain which was later recovered from their nasal swabs and tonsils. Pregnant sows vaccinated twice with purified gVI (IM) at a three week interval produced virus neutralizing antibodies in colostrum. Four-day-old sucking piglets born of vaccinated sows were passively protected by colostral antibodies against intranasal challenge with a lethal dose of virulent ADV. Sera from gVI-vaccinated pigs were distinguished from experimentally infected swine sera by their differential reactivity in enzyme-linked immunosorbent assay (ELISA) using four major viral glycoproteins (excluding gVI) as antigen purified by the use of lentil-lectin.